1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Lilly’s Eczema Contender Promising, But Needs Head-To-Head Data To Dent Dupixent Dominance

Also Vital For Partners Almirall

 
• By Andrew McConaghie

Topline results suggest lebrikizumab could outshine Sanofi’s Dupixent on safety and itch reduction in atopic eczema, but a direct comparison study is likely required to drive the message home.

Eli Lilly logo sign atop Lilly Biotechnology Center
Lilly is also awaiting FDA judgement on its JAK inhibitor Olumiant in atopic dermatitis, a fast expanding market for biologics.

Eli Lilly and Company and Almirall have released promising topline Phase III data from their anti-IL13 candidate lebrikizumab in eczema treatment, but will probably need to conduct a head-to-head trial to challenge the dominance of Dupixent in the market.

The data released showed that lebrikizumab resulted in at least 75% skin clearance in “more than half” of people with moderate-to-severe atopic dermatitis (AD), as measured on the EASI75 scale,...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

Summit’s Ivonescimab Shows Significance On PFS, But Not Overall Survival

 
• By Joseph Haas

In a study intended to show similar benefit in western patients, PD-1/VEGF-targeting ivonescimab met a progression-free survival endpoint, but missed on OS.

Sanofi Bid For Second COPD Approval Hurt By Mixed Itepekimab Data

 
• By Kevin Grogan

One Phase III trial hits but a second study misses by a mile.

In Brief: Neurocrine Details New Data For Schizophrenia Drug Moving To Phase III

 
• By Sushmita Panda

Neurocrine reports new details of positive Phase II results in schizophrenia and a favorable safety and cardiovascular profile for its first-in-class oral M4 agonist, now moving to Phase III trials.

Merck & Co./Daiichi Pull Patritumab Deruxtecan BLA On Disappointing OS

 
• By Jessica Merrill

Patritumab deruxtecan is the lead antibody drug conjugate in a $22bn deal signed between the two partners, with the decision marking a disappointing setback

More from R&D

Senti’s Computer-Logic Inspired Cell Therapy Shows Early Promise

 
• By Andrew McConaghie

The biotech believes its logic-gated cell therapies can get round the need for ‘clean targets’ which limit CAR-Ts and ADCs.

In Brief: Nicox Extends Cash Runway As Kowa Advances NCX 470 In Japan

 
• By Sushmita Panda

Eye drug is already in Phase III trials elsewhere, with results due in Q3. Nicox could earn up to a further €24.5m in milestones and royalties from Kowa alliance.

GSK’s Bet On Spero’s Oral cUTI Antibiotic Poised To Pay Off With New Phase III Data

 
• By Joseph Haas

Spero and partner GSK have Phase III non-inferiority data to support approval of tebipenem as the first oral antibiotic for complicated urinary tract infections.